BioDiscovery

Joining forces to advance medical innovation


We bring to entrepreneurs the necessary resources to develop medical innovations.

Sectors and stage

We invest in companies developing therapeutic products and medical technologies. Our investments cover a wide range of therapeutic areas to address unmet medical needs, and usually start once the company has obtained preclinical proof of concept with a drug candidate or device prototype.


Our investments

Interviews with our entrepreneurs

Genkyotex: support innovative entrepreneurs

BioDiscovery will prove to have been a key investor in the history of Genkyotex. Their team managed two financing rounds and played a decisive role in the transformation of Genkyotex from a private company to a listed company.

Elias Papatheodorou
CEO of Genkyotex

Jenavalve: work closely together

I’ve always very much respected and appreciated the unwavering support we’ve got from BioDiscovery.

Jan Keltjens
Endosense CEO

Transforming therapies

The next « big thing »


 

We actively participate in the advancement of major medical innovations. For example, in the field of antibodies, following investments in companies developing conventional monoclonal antibodies (U3 Pharma and PanGenetics, BioDiscovery 2), we sought technological innovations, which allowed modifying the specificity (Covagen, BioDiscovery 3), or enhancing the potency (Gamamabs, BioDiscovery 4) of these molecules. A further challenge consists of combining a specificity equivalent to that of antibodies with intracellular targeting. This would allow reaching currently intractable targets and is the focus of Complix (BioDiscovery 4).

Electricity is the new drug


 

The use of electricity to stimulate the nervous system to treat various pathologies represents another major medical innovation. Technological improvements in the size of generators or the precision of probes have catalyzed significant progress in this area, as reflected in Sapiens’ Deep Brain Stimulation product for Parkinson’s (BioDiscovery 3), Axonics’ product for the management of overactive bladder (BioDiscovery 4), and Autonomic Technologies’ treatment of patients suffering from cluster headache and migraine (BioDiscovery 4).

Our BioDiscovery team

Olivier Litzka
Partner
Gilles Nobécourt
Partner
Raphaël Wisniewski
Partner
Thierry Hercend
Venture Partner
Loan Hoang-Sayag
Venture Partner
Sofia Ioannidou
Director
Aneta Sottil
Investment Director
Mathieu Piéronne
Associate
Denis Dubuy
Analyst
Rémi Spagnol
Analyst
Hélène Bremaud
Assistant

Our BioDiscovery investments

Small molecules for the treatment of cancer

BioDiscovery
August 2018 / In portfolio

Antisense nucleotides for the treatment of neuromuscular rare disorders

BioDiscovery
July 2018 / In portfolio

Small molecules for the treatment of hepatitis B and NASH

BioDiscovery
June 2018 / In portfolio
Tricares

Development of minimally invasive treatment of tricuspid regurgitation

BioDiscovery
June 2018 / In portfolio

Antibodies for the treatment inflammation in renal failure

BioDiscovery
April 2018 / In portfolio
GreyWolf Therapeutics

Small molecules to increase tumor detection by the immune system

BioDiscovery
April 2018 / In portfolio

Technology platform producing tunable biologics for the treatment of cancer

BioDiscovery
April 2018 / In portfolio

Robotic assisted microsurgery platform

BioDiscovery
April 2018 / In portfolio

Novel enzymatic therapy for solid and liquid tumours

BioDiscovery
November 2017 / In portfolio

Naturally occurring molecule for the treatment of fibrotic diseases in the renal and cardiovascular

BioDiscovery
July 2017 / In portfolio

Gene therapy for the treatment of rare diseases in infants

BioDiscovery
June 2017 / In portfolio
IPO

Inhaled anti-fibrotic drug for the treatment of orphan respiratory disease

BioDiscovery
March 2017 / In portfolio

Next generation ablation catheter for the treatment of cardiac arrhythmias

BioDiscovery
March 2017 / In portfolio

Small molecules for the treatment of inflammatory lung pathologies

BioDiscovery
July 2016 / In portfolio

Small molecule for the treatment of progressive multiple sclerosis

BioDiscovery
March 2016 / In portfolio

Development of optimized therapeutic antibodies for the treatment of cancer

BioDiscovery
November 2015 / In portfolio

Small molecules as a therapeutic treatment for RSV infection

BioDiscovery
September 2015 / In portfolio

Phytic acid for the treatment of cardiovascular calcification

BioDiscovery
September 2015 / In portfolio

Development of neurostimulation devices for the treatment of Cluster Headache

BioDiscovery
May 2015 / In portfolio

Novel approach to increase efficacy and safety of marketed Alzheimer's drugs

BioDiscovery
May 2014
Sold

Neuromodulation technology for the treatment of incontinence

BioDiscovery
March 2014 / In portfolio
IPO

Anti-inflammatory peptides for the treatment of sepsis

BioDiscovery
February 2014 / In portfolio
Oncoethix

Small molecules for haematological cancer treatment

BioDiscovery
July 2013
Sold

Platform of scaffold proteins oriented against intracellular targets in oncology

BioDiscovery
June 2013 / In portfolio

Development of novel treatments to combat multi drug-resistant bacterial infections

BioDiscovery
April 2013 / In portfolio
Sapiens

Deep brain stimulation system for the treatment of Parkinson’s disease

BioDiscovery
June 2011
Sold

Development of inhibitors of enzymes involved in oxydative stress

BioDiscovery
May 2011 / In portfolio

Mobile diabetes management system

BioDiscovery
January 2011 / In portfolio
Parvulus Medical

Annuloplasty ring for pediatric cardiac valve repair

BioDiscovery
October 2010
Sold

Development of small molecules for the treatment of Type 2 diabetes

BioDiscovery
June 2010 / In portfolio

New class of therapeutics based on the proprietary Fynomer protein scaffold

BioDiscovery
January 2010
Sold

Mocules for the treatment of inflammatory diseases

BioDiscovery
December 2009
Sold

Development of innovative molecule drugs for the treatment of neurodegenerative diseases

BioDiscovery
October 2009 / In portfolio

Force-sensing ablation catheters for the treatment of cardiac arrhythmias

BioDiscovery
August 2009
Sold

Glycosylation platform for generation of conjugated vaccines

BioDiscovery
February 2009
Sold

Ultrasound technology measuring tissue elasticity for cancer detection

BioDiscovery
October 2008 / In portfolio

Development of a non-invasive valve replacement technology

BioDiscovery
August 2007 / In portfolio

Development of a new class of aptamers as therapeuticals

BioDiscovery
April 2007 / In portfolio

Orthopedic implants with new traceability system

BioDiscovery
February 2007
Sold

Development and commercialisation of a low X ray doses 3D imaging device

BioDiscovery
November 2005 / In portfolio

Development of in vitro diagnostic tests for early detection of tumor biomarkers

BioDiscovery
October 2005
Sold

Contact us


I am a business person
I am an investor
Other
Surname & given name :
Company :
Telephone :
E-mail :
My message is :